All Issue

2022 Vol.52, Issue 3 Preview Page

Original Article

Incidence of Carbapenem-Resistant Enterobacteriaceae and Carbapenemase- Producing Enterobacteriaceae Gene Distribution in Ulsan, Korea, 2018~2021
Bo-Woon Kim1*
,
Young-Kyung Jo1
,
Gyeong-Nam Kim1
,
Jung-Yun Hwang1
,
Mi-Yeon Hong1
,
Won-Dug Seo1
,
Suk-Nam Hwang1
1Ulsan Metropolitan Government Research Institute of Public Health and Environment, 157, Munsu-ro, Nam-gu, Ulsan 44642, Republic of Korea
*kimbowoon@korea.kr
30 September 2022. pp. 103-114
PDF XML Citation
Abstract

This study was conducted on the incidence of CRE infection and CPE gene distribution in Ulsan to prepare basic data for preventing the spread of CRE infection by confirming the regional characteristics of CRE infection. The results of the CRE infection test from 2018 to 2021 conducted by the Ulsan Metropolitan Government Research Institute of Public Health and Environment in accordance with the experimental method of the Korea Disease Control and Prevention Agency’s SOP on CRE infection test were analyzed for the study. Through the analysis, it was confirmed that the positive rate of ‘CRE or CPE’ in the samples surveyed increased from 92.83% in 2018 to 97.62% in 2021. In the analyzed ‘CRE (including CP-CRE)’ samples, Ertapenem resistance was the most common at 94.34%, Imipenem resistance 65.37%, Meropenem resistance 63.34%, and Doripenem resistance 52.70%. Regarding the average distribution of ‘CRE (including CP-CRE)’ by genus for the four years, the genus Klebsiella was isolated the most with an average of 72.04%, followed by the genus Escherichia (10.81%), the genus Enterobacter (9.54%), and the genus Citrobacter (1.27%.). From 2018 to 2021, the proportion of ‘CP-CRE’ increased significantly from 59.07% to 68.45% and the types of genus and species identified as ‘CP-CRE’ were diversified during the same period. The distribution of the detected CPE genes were highest in KPC (89.31%), and NDM (8.53%), and the distribution of CPE gene subtypes also varied. It is expected that this study can be used as basic data for preparing suitable countermeasures against CRE infection in the community in the future.

Keywords
CRE
CPE
CP-CRE
Carbapenem
Antibiotics-resistance
References
1

El-Gamal MI, Brahim I, Hisham N, Aladdin R, Mohammed H, Bahaaeldin A. Recent updates of carbapenem antibiotics. Eur J Med Chem 2017;131:185-95.

10.1016/j.ejmech.2017.03.02228324783
2

Meletis G. Carbapenem resistance: overview of the problem and future perspectives. Ther Adv Infect Dis 2016;3:15-21.

10.1177/204993611562170926862399PMC4735501
3

Park S-Y. Transmission and management of carbapenem-resistant enterobacteriaceae. Proceedings of the Korean Society of Internal Medicine Spring Conference 2019;2019:249-51.

4

CDC, NCEZID, Division of Healthcare. CRE Technical Information [Internet]. Centers for Disease Control and Prevention. 2019. Available from: https://www.cdc.gov/hai/organisms/cre/technical-info.html#Definition

5

Sawa T, Kooguchi K, Moriyama K. Molecular diversity of extended-spectrum β-lactamases and carbapenemases, and antimicrobial resistance. J Intensive Care 2020;8:13.

10.1186/s40560-020-0429-632015881PMC6988205
6

Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis 2017;215:S28-S36.

10.1093/infdis/jiw28228375512PMC5853342
7

KDCA, Medical Infection Control Division. Carbapenem-resistant Enterobacteriaceae (CRE) Infection [Internet]. Infectious Disease Portal. 2020. Available from: https://www.kdca.go.kr/npt/biz/npp/portal/nppSumryMain.do?icdCd= NB0020&icdgrpCd 02&icdSubgrpCd=

8

CLSI. Performance Standards for Antimicrobial Susceptibility Testing M100-S26. Wayne, PA: CLSI, 2016.

9

KDCA. Integrated guidelines for diagnostic tests for legal infectious diseases 3. 1st ed. Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do: KDCA, 2021.

10

Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-Resistant Enterobacteriaceae: Epidemiology and Prevention. Clin Infect Dis 2011 Jun;53:60-7.

10.1093/cid/cir20221653305
11

Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011;17:1791-8.

10.3201/eid1710.11065522000347PMC3310682
12

Korean Society of Infectious Diseases. Textbook of Guideposts to Antimicrobial. 4th ed. Pa-ju Publishing Complex: Jooyeon Jang; 2019.

13

Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm!. Trends Mol Med 2012;18:263-72.

10.1016/j.molmed.2012.03.00322480775
14

Queenan AM, Bush K. Carbapenemases: the versatile β-lactamases. Clin Microbiol Rev 2007;20:440-58.

10.1128/CMR.00001-0717630334PMC1932750
15

Vasoo S, Barreto JN, Tosh PK. Emerging issues in gram-negative bacterial resistance: an update for the practicing clinician. Mayo Clin Proc 2015;90:395-403.

10.1016/j.mayocp.2014.12.00225744116
16

Kopotsa K, Osei Sekyere J, Mbelle NM. Plasmid evolution in carbapenemase‐producing Enterobacteriaceae: a review. Ann N Y Acad Sci 2019;1457:61-91.

10.1111/nyas.1422331469443
17

Tamma PD, Goodman KE, Harris AD, Tekle T, Roberts A, Taiwo A, et al. Comparing the outcomes of patients with carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae bacteremia. Clin Infect Dis 2017;64:257-64.

10.1093/cid/ciw74128013264PMC5241781
18

Joo SJ, Kim MK, Shin EK, Kim JY, Yoo JI. Analysis of resistance trends and characteristics of Carbapenem-resistant Enterobacteriaceae (CRE) isolated in Korea for 2017-2020. KDCA 2021;14:3790-804.

19

Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008;29:1099-106.

10.1086/59241218973455
20

Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008;52:1028-33.

10.1128/AAC.01020-0718086836PMC2258527
21

Chen LF, Anderson DJ, Paterson DL. Overview of the epidemiology and the threat of Klebsiella pneumoniae carbapenemases (KPC) resistance. Infect Drug Resist 2012;5:133-41.

10.2147/IDR.S2661323055754PMC3460674
22

Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009;9:228-36.

10.1016/S1473-3099(09)70054-4
23

Bratu S, Landman D, Haag R, Recco R, Eramo A, Alam M, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 2005;165:1430-5.

10.1001/archinte.165.12.143015983294
24

Woodford N, Tierno PM Jr, Young K, Tysall L, Palepou MF, Ward E, et al. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A β-lactamase, KPC-3, in a New York medical center. Antimicrob Agents Chemother 2004;48:4793-9.

10.1128/AAC.48.12.4793-4799.200415561858PMC529220
25

Cai JC, Zhou HW, Zhang R, Chen GX. Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli isolates possessing the plasmid-mediated carbapenem-hydrolyzing β-lactamase KPC-2 in intensive care units of a Chinese hospital. Antimicrob Agents Chemother 2008;52:2014-8.

10.1128/AAC.01539-0718332176PMC2415814
26

Lee HK, Park YJ, Kim JY, Chang E, Cho SG, Chae HS, et al. Prevalence of decreased susceptibility to carbapenems among Serratia marcescens, Enterobacter cloacae, and Citrobacter freundii and investigation of carbapenemases. Diagn Microbiol Infect Dis 2005;52:331-6.

10.1016/j.diagmicrobio.2005.04.01215994052
27

Borer A, Saidel-Odes L, Riesenberg K, Eskira S, Peled N, Nativ R, et al. Attributable mortality rate for carbapenem- resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol 2009;30:972-6.

10.1086/60592219712030
28

Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008;29:1099-106.

10.1086/59241218973455
29

Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008;52:1028-33.

10.1128/AAC.01020-0718086836PMC2258527
30

Palzkill T. Metallo‐β‐lactamase structure and function. Ann N Y Acad Sci 2013;1277:91-104.

10.1111/j.1749-6632.2012.06796.x23163348PMC3970115
31

Dong LT, Espinoza HV, Espinoza JL. Emerging superbugs: the threat of carbapenem resistant enterobacteriaceae. AIMS Microbiol 2020;6:176-82.

10.3934/microbiol.202001233134739PMC7595834
32

Nordmann P, Poirel L, Toleman MA, Walsh TR. Does broad-spectrum β-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria? J Antimicrob Chemother 2011;66:689-92.

10.1093/jac/dkq52021393184
33

Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis 2011;11:355-62.

10.1016/S1473-3099(11)70059-7
34

Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010;10:597-602.

10.1016/S1473-3099(10)70143-2
35

Shahid M. Environmental dissemination of NDM-1: time to act sensibly. Lancet Infect Dis 2011;11:334-5.

10.1016/S1473-3099(11)70074-3
36

Cornaglia G, Giamarellou H, Rossolini GM. Metallo-β-lactamases: a last frontier for β-lactams? Lancet Infect Dis 2011;11:381-93.

10.1016/S1473-3099(11)70056-1
37

Meletis G, Chatzidimitriou D, Malisiovas N. Double-and multi-carbapenemase-producers: the excessively armored bacilli of the current decade. Eur J Clin Microbiol Infect Dis 2015;34:1487-93.

10.1007/s10096-015-2379-925894987
38

Cho SY, Huh HJ, Baek JY, Chung NY, Ryu JG, Ki CS, et al. Klebsiella pneumoniae co-producing NDM-5 and OXA-181 carbapenemases, South Korea. Emerg Infect Dis 2015;21:1088-9.

10.3201/eid2106.15004825988911PMC4451906
39

Park SH, Park SH, Kim JS, Yu JK, Kim JK, Suh HS, et al. Genetic Distribution of Carbapenem-Resistant Enterobacteriaceae in Seoul Korea, 2018~ 2020. J Bacteriol Virol 2022;52:28-38.

10.4167/jbv.2022.52.1.028
40

Siegel JD, Rhinehart E, Jackson M, Chiarello L. Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control 2007;35:S165-93.

10.1016/j.ajic.2007.10.00618068814
41

KDCA. The importance of one health approach [Internet]. One health AMR. 2022. Available from: https://www. kdca.go.kr/nohas/aboutOH/OHimportanceOfaccess.do

Information
  • Publisher :The Korean Society for Microbiology and The Korean Society of Virology
  • Publisher(Ko) :대한미생물학회‧대한바이러스학회
  • Journal Title :JOURNAL OF BACTERIOLOGY AND VIROLOGY
  • Volume : 52
  • No :3
  • Pages :103-114
  • Received Date : 2022-07-25
  • Revised Date : 2022-09-21
  • Accepted Date : 2022-09-22
  • DOI :https://doi.org/10.4167/jbv.2022.52.3.103
Journal Informaiton JOURNAL OF BACTERIOLOGY AND VIROLOGY JOURNAL OF BACTERIOLOGY AND VIROLOGY
  • NRF
  • 임플란트학회 전용 배너
  • KOFST
  • crossref crossmark
  • crossref cited-by
  • crossref funder-registry
  • crosscheck
  • orcid
  • open access
  • ccl
Journal Informaiton Journal Informaiton - close